Last checked at 12 Jan 2018 17:13
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Maryland, USA - 12 January 2018: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 18,293 new shares of common stock of $0.01 each in the Company (the "Common Stock") were issued from the blocklisting facility granted 5 May 2017.
The total issued stock capital of the Company has consequently increased to 50,896,376 Common Stock. There is no Common Stock held in treasury. Therefore, the total number of voting rights in the Company is 50,896,376. Stockholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the capital of the Company.
The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 35,383,268 and the number of restricted shares of Common Stock trading under the symbol 'MXCR' is 15,513,108. The number of Common Stock capable of being issued under the blocklisting facility is 918,151 Common Stock.
For further information please contact:
MaxCyte | +1 301 944 1660 |
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer | |
Nominated Adviser and Broker Panmure Gordon Freddy Crossley (Corporate Finance) Fabien Holler Tom Salvesen (Corporate Broking)
| +44 (0) 20 7886 2500
|
Financial PR Adviser Consilium Strategic Communications | +44 (0)203 709 5700 maxcyte@consilium-comms.com |
Mary-Jane Elliott Chris Welsh Lindsey Neville |
About MaxCyte
MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.
MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.
Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.
For more information visit http://www.maxcyte.com/